Pulmonary Arterial Hypertension Treatment Industry Poised to Surpass US$ 6.6 Billion by 2028-FMI Report

The pulmonary arterial hypertension (PAH) treatment industry stands as a beacon of hope for individuals grappling with this rare but serious condition that affects the heart and lungs. PAH involves abnormally high blood pressure in the arteries that connect the heart and lungs, leading to reduced blood flow and strain on the heart. The treatment landscape for PAH has evolved significantly, offering innovative therapies that target the underlying mechanisms of the disease. With advancements in drug development, personalized approaches, and a growing understanding of PAH’s complexities, the market plays a vital role in improving patients’ quality of life and extending their lifespan.

One of the hallmarks of the PAH treatment market is its focus on precision therapies that target specific pathways involved in the disease’s progression. These therapies work by dilating the blood vessels, reducing strain on the heart, and improving blood flow. By addressing the root causes of PAH, these treatments offer patients more than just symptom relief – they provide an opportunity for improved functional capacity and prolonged survival.

Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-1218

Owing to non-responsive nature of several advance pharmacotherapies and high diagnosis and treatment costs, researchers and medical practitioners in the global pulmonary arterial hypertension treatment market are continually working on favorable and effective alternative treatment models and increase survival rate among the patients with pulmonary arterial hypertension.

The global pulmonary arterial hypertension treatment market is expected to reach US$ 5.7 billion by 2022. The market is expected to reach US$ 6.6 billion by 2028, growing at a healthy 2.5% CAGR.

Cancer Protein Molecules Tested for Potential Therapeutic Use- to Prevent Pulmonary Arteries ‘Scarring’

Scarring or Fibrosis, in pulmonary arterial hypertension, is an important cause of damage to pulmonary arteries, which in turn, strains the heart functions- eventually leading to breathlessness. Recently, researchers from Brigham and Women’s Hospital conducted a study using network medicine- a method of establishing correlation between proteins, pathways and more- and identified the cancer protein NEDD9 and its molecular mechanisms as a potential treatment for PAH patients. The study has identified that a specific amino acid residue in the cancer protein is expected to play a crucial role in controlling and regulating the severe consequences of scarring.

BH4- Factor Controlling Production of Nitric Oxide- Shows Promising Result on Rat Model; Results Show Lower Lung Hypertension

Researchers at Imperial College London and Bar-Ilan University, Israel explored the properties of naturally occurring tetrahydrobiopterin (BH4) and its subsequent role in effective treatment for lung hypertension and right heart failure. BH4 controls the production of endothelial nitric oxide synthase (eNOS) in the human body. eNOS produces nitric oxide which is important for healthy endothelial cells- forming the inside lining of blood vessels. Nitric oxide is responsible for dilating blood vessels, working to lower lung blood pressure.

The study- conducted on a rats first in injected with chemical triggering pulmonary hypertension and then an injection of BH4, showed signs of decreased lung pressure, stronger heart contractions and, enlarged heart.  The rats were then given BH4 in food before the chemical that previously induced pulmonary hypertension. As a result of which, no thick layers of smooth muscles were developed- often leading to lung hypertension.

Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-1218

After the phase 1 of clinical trials, the patients- administered BH4 orally, showed improved exercise capacity- an indicator of low pressure in lungs. It is anticipated that BH4, when given controlled measure could prove to a valuable treatment for pulmonary arterial hypertension patients who otherwise are not responsive to regular medication.

With Treatment Options, ‘Accurate Risk Measuring’ Tools is the Need of the Hour

Although measurable efforts are being made in the global pulmonary arterial hypertension treatment market, the survival rate among PAH patients continues to remain low.  According to studies, the average life expectancy of PAH patient is approximately 3 years from symptom onset- being at a risk of disease progression and frequent hospitalizations. Several studies indicate that early diagnosed and ‘low-risk’ patients stand a chance of improved survival if the risk is calculated accurately. Experts have expressed the need to develop appropriate and accurate risk prediction tools improve treatment outcomes in PAH patients.

Pulmonary Arterial Hypertension Treatment Market by Category

Drug Type :

• Vasodilators
• Phosphodiesterase 5 (PDE 5) Inhibitors
• Endothelin Receptor Antagonists (ERA)
• Soluble Guanylate Cyclase (SGC) Stimulator

Distribution Channel :

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region :

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific
• China
• Japan
• Middle East & Africa

Unlock exclusive insights with our expert analysts :
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1218

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube